SCHEMBL4928496

SCHEMBL4928496

Cc1nc(C(=O)N2CCOCC2)cc2c(Nc3cccc4c3CCO4)c(C(N)=O)cnc12

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.54
CSF1R P07333 3/20 0.42
CYP3A4 P08684 3/20 0.39
CYP2C9 P11712 3/20 0.39
EED O75530 2/20 0.39
SUZ12 Q15022 2/20 0.39
EZH2 Q15910 2/20 0.39
MTNR1B P49286 1/20 0.36
KCNH2 Q12809 1/20 0.36
NR3C1 P04150 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
CAMK1D Q8IU85 1/20 0.35
RBBP4 Q09028 1/20 0.35
AEBP2 Q6ZN18 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4928787 0.94 PDE4B (0.55) PDE4BCSF1RCYP3A4CYP2C9EED
SCHEMBL4928653 0.94 PDE4B (0.54) PDE4BCSF1RCYP3A4CYP2C9EED
SCHEMBL4930190 0.89 PDE4B (0.52) PDE4BCSF1RCYP3A4CYP2C9EED
Trifluoroacetic Acid SCHEMBL4920764 0.88 PDE4B (0.49) PDE4BCSF1RCYP3A4CYP2C9EED
SCHEMBL4928534 0.88 PDE4B (0.59) PDE4BCSF1RCYP3A4CYP2C9EED
SCHEMBL5457430 0.87 PDE4B (0.55) PDE4BCSF1RCYP3A4CYP2C9CNR1
SCHEMBL4924230 0.86 PDE4B (0.57) PDE4BCSF1RCYP3A4CYP2C9MTNR1B
SCHEMBL4923595 0.85 PDE4B (0.53) PDE4BCSF1RCYP3A4CYP2C9MTNR1B
SCHEMBL4299675 0.83 PDE4B (0.60) PDE4BCSF1RCYP3A4CYP2C9MTNR1B
Trifluoroacetic Acid SCHEMBL4925209 0.83 PDE4B (0.46) PDE4BCSF1RCYP3A4CYP2C9EED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors GLAXO GROUP LIMITED 2008-06-19 US disclosed
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors GLAXO GROUP LIMITED 2008-06-19 US disclosed
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors GLAXO GROUP LIMITED 2008-06-19 US disclosed
WO-2006097340-A1 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146563-A1 1,7-Naphthyridines as Pde4 Inhibitors PDE4A, PDE3B, PDE4B PDE4B 3/4885CSF1R 4095/4885CYP3A4 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.